HSBC Holdings
CRDF icon

HSBC Holdings’s Cardiff Oncology CRDF Stock Holding History

HSBC Holdings’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8K Buy
+28,996
New +$46K ﹤0.01% 2879

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HSBC Holdings's CRDF Position: Q2 2026 in Review

HSBC Holdings opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 28,996 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #2879 among its holdings.

105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • HSBC Holdings held 28,996 shares of Cardiff Oncology worth $36.8K as of Q2 2026.
  • Cardiff Oncology was a new HSBC Holdings position in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2879 holding.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.